Roth Capital Upgrades Monogram Orthopaedics (NASDAQ:MGRM) to “Strong-Buy”

Roth Capital upgraded shares of Monogram Orthopaedics (NASDAQ:MGRM) to a strong-buy rating in a research note issued to investors on Monday,Zacks.com reports.

Separately, Roth Mkm began coverage on shares of Monogram Orthopaedics in a report on Monday. They set a “buy” rating and a $4.00 price objective on the stock.

Monogram Orthopaedics Trading Up 9.3 %

Shares of MGRM stock opened at $2.46 on Monday. The company has a market cap of $84.40 million, a PE ratio of -5.23 and a beta of 2.01. Monogram Orthopaedics has a 12-month low of $1.53 and a 12-month high of $4.90. The business’s fifty day simple moving average is $2.26 and its 200-day simple moving average is $2.39.

Hedge Funds Weigh In On Monogram Orthopaedics

Several hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC increased its holdings in Monogram Orthopaedics by 1,267.4% in the 3rd quarter. Geode Capital Management LLC now owns 210,144 shares of the company’s stock worth $557,000 after buying an additional 194,776 shares during the period. State Street Corp acquired a new position in Monogram Orthopaedics during the third quarter valued at $62,000. Finally, Barclays PLC purchased a new stake in Monogram Orthopaedics in the third quarter valued at $29,000. 0.45% of the stock is owned by institutional investors and hedge funds.

Monogram Orthopaedics Company Profile

Monogram Orthopaedics, Inc focuses on developing a product solution architecture to enable patient-optimized orthopaedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures.